Kitasato University Hospital has set up a call center to secure clinical trial patients by applying the new coronavirus infection of the antiparasitic drug "ivermectin".In order to increase the number of clinical trial patients who cannot be secured due to corona damage, the call center will endeavor to secure clinical trial patients in Tokyo with the cooperation of the Tokyo Metropolitan Medical Association.
According to Kitasato University Hospital, to secure clinical trial patients, the private hospital will introduce patients suspected of having a new coronavirus infection who visited a private hospital in Tokyo, and the call center will provide information to patients who wish to participate in the clinical trial. Mechanism to do.At the same time, the call center will also perform the primary selection of patients according to the clinical trial conditions.For the time being, it will start in Minato Ward and Suginami Ward, which are close to medical institutions that carry out treatment, and then expand throughout Tokyo.
Ivermectin is an existing antiparasitic drug, and Satoshi Omura, a special honorary professor at Kitasato University, discovered a compound that strongly acts on parasites and other nerves and has almost no effect on human nerves, and was commercialized by Merck, a US pharmaceutical company.It is used for the treatment of the new corona in some countries, but no large-scale clinical trials have been conducted to confirm its efficacy.
Kitasato University Hospital began clinical trials for the application of the new corona in September 2020, but due to the medical pressure of the corona sickness, it was not possible to adequately respond, and the number of registered cases as of June was only over half of the planned number. ing.
